The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 6 March 2026•Updated 6 March 2026•

1 min read

Day One Stock Surges 65% Following $2.5 Billion Acquisition by Servier

Key Facts

1Servier agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash.

3 months ago

Version History

Version 13 months ago

What changed: Updated the story to include the 65% stock surge, the 70% premium details, and identified the lead drug Ojemda as the primary driver for the acquisition's strategic value.

French pharmaceutical group Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in an all-cash deal valued at $2.5 billion. Following the announcement, Day One's stock surged 65% on Friday morning, representing a nearly 70% premium over its previous closing price. The stock is currently trading at more than twice its price at the start of 2026, driven by the significant acquisition premium. Market analysts view the deal as a major validation of Day One's lead program, Ojemda (tovorafebin), a breakthrough treatment for pediatric low-grade glioma. This strategic move allows Servier to significantly bolster its global oncology portfolio and its pipeline for rare pediatric diseases. The transaction is slated to close in the second quarter of 2026, subject to customary regulatory approvals and shareholder consent.